Sequence: Ac-RLLRLLLRLWRRLLRLLR-NH2
| Experiment Id | EXP002016 |
|---|---|
| Paper | A New Amphipathic, Amino-Acid-Pairing (AAP) Peptide as siRNA Delivery Carrier: Physicochemical Chara |
| Peptide | C6 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | ~0.75–2.0 µM (with 50 nM siRNA at MR 15–40); also used 4–40 µM in characterization |
| Rna Concentration | 50 nM (cell uptake); 100 nM (DLS/zeta); 6 µM (ITC); 0.3 µg per lane (gel) |
| Mixing Ratio | peptide:siRNA molar ratio 15:1, 25:1, 40:1 (uptake); stability starts ~10:1 |
| Formulation Format | noncovalent peptide–siRNA complexes / coassemblies |
| Formulation Components | C6 peptide + siRNA (GAPDH or eGFP); prepared in RNase-free water; cells treated in Opti-MEM |
| Size Nm | 50.00 |
| Zeta Mv | 30.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | CHO-K1 (Chinese hamster ovary) |
| Animal Model | |
| Administration Route | |
| Output Type | uptake / localization |
| Output Value | Higher siRNA uptake vs Lipofectamine 2000 (FACS); cytoplasmic/perinuclear punctate Cy3 signal by fluorescence microscopy |
| Output Units | |
| Output Notes | Uptake increases with peptide:siRNA molar ratio; punctate perinuclear distribution suggests endocytosis; no in vitro gene knockdown reported |
| Toxicity Notes | No significant toxicity; cell viability not reduced below ~85% up to MR 40; Lipofectamine showed higher toxicity |
| Curation Notes |